HelpAcademyLoginJoin us as a Member

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

NCT06625320 · RASolute 302 Phase 3Active, not recruiting

Lead sponsor
Revolution Medicines, Inc. (Industry)
Enrollment
500 (actual)
Start date
16 Oct 2024
Primary completion
Jun 2026 (estimated)
Study completion
1 Dec 2027
Last update posted
2 Jun 2026

Design

Study type
Interventional
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel
Masking
None
Arms
2

Interventions

  • RMC-6236 Drug
  • Gemcitabine Drug
  • nab-paclitaxel Drug
  • Irinotecan Drug
  • Liposomal irinotecan Drug
  • 5-fluorouracil Drug
  • leucovorin Drug
  • Oxaliplatin Drug

Conditions and primary outcome

  • Pancreatic Cancer
  • PDAC
  • PDAC - Pancreatic Ductal Adenocarcinoma

Primary outcome

Progression free survival (PFS) in the RAS G12-mutant population (Up to approximately 3 years); Overall survival (OS) in the RAS G12-mutant population (Up to approximately 3 years)

Posted results on ClinicalTrials.gov

Results posted on ClinicalTrials.gov: No

Results from company and journal sources

No editor-confirmed results are on record for this study.

Publications

1 on PubMed

  1. Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer.

    The New England journal of medicine · 2026 Jul 23

    PubMed 42223072 (opens in a new tab)DOI 10.1056/NEJMoa2605555 (opens in a new tab)

Citations from PubMed, U.S. National Library of Medicine; abstracts are not stored. A publication lists this study’s NCT number and may be a review that cites many studies.

CT-VCA trial quality

About CT-VCA

Loading CT-VCA scores…

Data integrity

Compare what the registry, company releases, FDA documents and publications say about this study.

Drugs on HealthTrade

Source

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.

Nothing on this page is medical or investment advice.